



Luxembourg, 2 July 2024

**Scientific Committee on Consumer Safety (SCCS)
8th Plenary meeting 2022-2026**

20 June 2024, Luxembourg (hybrid)

Minutes

1. WELCOME AND APOLOGIES (CHAIR: PROF. Q. CHAUDHRY)

The Chair welcomed all participants, including the SCHEER representative and DG GROW. The agenda was adopted. One apology was received.

The minutes of the previous plenary meeting were adopted by the SCCS via written process and published on the website: [SCCS - Plenary sessions 2022 - 2026 \(europa.eu\)](https://europa.eu/sccs/plenary-sessions-2022-2026)

The Chair invited participants to declare any interest regarding matters on the agenda. None of the participants declared any new interest conflicting with the matters on the agenda. Any interest already reported in the annual declaration remains valid.

2. LIST OF POINTS DISCUSSED

2.1 NEW REQUESTS/MANDATES/ GENERAL INFORMATION FROM DG GROW

No new mandate was discussed or adopted: [SCCS - Mandates | Public Health \(europa.eu\)](https://europa.eu/sccs/mandates-public-health)

2.2. DRAFT OPINIONS

WG cosmetic ingredients

COMMENTS ON ADOPTED OPINIONS

The final Opinion on Silver was adopted together with the SCCS responses to the comments received; the final text will be published on [SCCS - Opinions \(europa.eu\)](https://europa.eu/sccs/opinions).

The following Opinions were discussed together with the SCCS responses to the comments received; the final texts will be discussed in the next WG meeting and might be adopted by written procedure during or after the summer:

1. Triphenylphosphate
2. Citral
3. Acetylated vetiver oil

DRAFT OPINIONS DISCUSSED

The following preliminary Opinions were discussed and will be further discussed in the WG meetings:

1. Biphenyl-2-ol and Sodium 2-biphenylolate (OPP-SOPP) - **CMR exemption**
2. Ethylhexyl Methoxycinnamate (EHMC-OMC): a request to the Applicants has been prepared.
3. Prostaglandin and analogues: ‘Ethyl Tafluprostamide’ (DDDE) (CAS No. 1185851-52-8, EC No. 867-521-0), Methylamido-Dihydro-Noralfaprostal (MDN) (CAS No. 155206-01-2, EC No.-) and Isopropyl Cloprostenate (IPCP) (CAS No. 157283-66-4, EC No.-) used in cosmetics products

WG nanomaterials

The Chair of the WG presented an update of the work.

- Three coatings for TiO₂ (nano) – commenting period until 22 July:
see [SCCS - Opinions - European Commission \(europa.eu\)](https://ec.europa.eu/sccs/)
- Hydroxyapatite (HAP) – submission IV (nano) – ON HOLD

3. INFORMATION FROM COMMISSION/ CHAIRS / MEMBERS

Vice-Chair reported on the participation in PARERE¹ meeting held end of May.

4. ANY OTHER BUSINESS

Next plenary meeting:

- 25 October 2024,
- 27 March 2025,
- 26 June 2025

¹ [PARERE - EURL ECVAM Network for Preliminary Assessment of Regulatory Relevance - European Commission \(europa.eu\)](https://ec.europa.eu/sccs/)